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Abstract  1 
Spinal Muscular Atrophy (SMA), traditionally described as a predominantly childhood 2 
form of motor neuron disease, is the leading genetic cause of infant mortality. 3 
Although motor neurons are undoubtedly the primary affected cell type, the severe 4 
infantile form of SMA (Type I SMA) is now widely recognised to represent a 5 
multisystem disorder where a variety of organs and systems in the body are also 6 
affected. Here, we report that the spleen is disproportionately small in the 7 
‘Taiwanese’ murine model of severe SMA (Smn
-/-
;SMN2
tg/0
), correlated to low levels 8 
of cell proliferation and increased cell death. Spleen lacks its distinctive red 9 
appearance and presents with a degenerated capsule and a disorganized fibrotic 10 
architecture. Histologically distinct white pulp failed to form and this was reflected in 11 
an almost complete absence of B lymphocytes necessary for normal immune 12 
function. In addition, megakaryoctyes persisted in the red pulp. However, the 13 
vascular density remained unchanged in SMA spleen. Assessment of the spleen in 14 
SMA patients with the infantile form of the disease indicated a range of pathologies. 15 
We conclude that development of the spleen fails to occur normally in SMA mouse 16 
models and human patients. Thus, further analysis of immune function is likely to be 17 
required in order to fully understand the full extent of systemic disease pathology in 18 
SMA. 19 
  20 
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Introduction 1 
 2 
A significant depletion of the cell-ubiquitous Survival of Motor Neuron (SMN) protein 3 
causes Spinal Muscular Atrophy (SMA). Homozygous deletion or mutation of the 4 
telomeric SMN1 gene results in a complete failure of functional protein production, 5 
and cell and embryonic survival is only assured by the production of SMN protein by 6 
a centromeric copy gene: SMN2 (Monani et al., 1999). Due to alternative splicing of 7 
exon 7, SMN2 produces only ~10% fully functional SMN protein (Monani et al., 8 
2000). This small amount of SMN protein is sufficient to ensure cell and embryonic 9 
survival, but is insufficient to prevent disease (Monani et al., 1999).  10 
 11 
SMA is the most common inherited cause of infant mortality with a pan-ethnic 12 
incidence of ~1 in 11,000 live births (Sugarman et al., 2012). The disease is primarily 13 
characterised by degeneration of α-motor neurones in the ventral horn of the spinal 14 
cord, with relative sparing of other cholinergic neuronal populations (Powis and 15 
Gillingwater, 2016). Skeletal muscle atrophy and weakness is generalized in the 16 
infantile phenotype but more severely affects proximal muscles in the intermediate 17 
and milder phenotypes. However, mounting evidence from patients and animal 18 
models suggests that SMA is a multisystem disorder, at least in the most severe 19 
phenotypes with prenatal or early infantile onset of involvement (SMA types 0 and 20 
1; (Hamilton and Gillingwater, 2012, Shababi et al., 2014)). For example, in the more 21 
severe murine models of SMA with juvenile lethality, pathological changes have 22 
been reported in skeletal muscle (Mutsaers et al., 2011), selected brain regions such 23 
as the hippocampus (Wishart et al., 2010), glial cells (Rindt et al., 2015, Hunter et al., 24 
2014), bone (Shanmugarajan et al., 2009), heart (Shababi et al., 2010),vasculature 25 
(Somers et al., 2012, Somers et al., 2016), lung (Schreml et al., 2012), and pancreas 26 
(Bowerman et al., 2012), with additional recent reports noting defects in testis 27 
(Ottesen et al., 2016) and the gastrointestinal tract (Sintusek et al., 2016). In human 28 
subjects, similar defects have been shown in muscle (Martínez-Hernández et al., 29 
2009), brain (Ito et al., 2004), heart (Rudnik-Schoneborn et al., 2008), vasculature 30 
(Rudnik-Schoneborn et al., 2010, Araujo et al., 2009, Somers et al., 2016), and 31 
pancreas (Bowerman et al., 2012).  32 
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 1 
Preliminary reports have suggested that there may be growth retardation 2 
phenotypes in lymphoid tissues from SMA mice, including thymus and spleen (Dachs 3 
et al., 2011). Given the importance of SMN for vascular development (Somers et al., 4 
2012, Somers et al., 2016), and the dependence on normal vascularity for 5 
development of the spleen, we were keen to determine the extent to which the 6 
spleen is affected in SMA, as well as the extent to which splenic pathology can be 7 
considered a downstream consequence of defective vascular development and 8 
maturation. 9 
 10 
The spleen fulfils two major functional roles; first, to filter blood by removing 11 
senescent red blood cells in a macrophage filled, sieve-like network of open 12 
sinusoids (Terada et al., 2010); and second, as a secondary lymphoid organ 13 
responsible for the generation of an immune response and innate immunity (Cesta, 14 
2006, Mebius and Kraal, 2005). This immune response arises in the white pulp 15 
compartment of the spleen, where T-cell zones and B-cell follicles initiate antigen-16 
specific responses necessary to combat blood-borne infections (Bronte and Pittet, 17 
2013). The first crucial stage of white pulp development is the accumulation of B-18 
cells around the splenic vasculature (Neely and Flajnik, 2015), but as there are no 19 
afferent lymph vessels present in the spleen, influx of leukocytes occurs directly 20 
from the blood (Bronte and Pittet, 2013). Without this aggregation of B-cells no 21 
functional white pulp will form (Myers et al., 2013), while the continued presence of 22 
B-cells supports white pulp maintenance (Wang et al., 2011).  23 
 24 
Here, we report that the spleen appears relatively normal at birth in SMA mice (a 25 
pre-symptomatic time-point), but then fails to match whole animal growth over the 26 
immediate post-natal period as the disease manifests and progresses. It fails to 27 
develop a normal cellular architecture, has significantly decreased cell density and 28 
fails to develop segmented red and white pulp areas. This decreased size and cell 29 
density correlate with reduced levels of cell proliferation and increased cell death. 30 
Significantly, there is an almost complete failure of B-cell accumulation, and relative 31 
levels of circulating lymphocytes are decreased.  In addition, unusually high 32 
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concentrations of megakaryocytes are present in the red pulp. Moreover, post-1 
mortem examination of the spleen in a cohort of SMA type I patients who died from 2 
a variety of causes reveals a range of pathologies, some of which also suggest 3 
abnormal development or acquired splenic dysfunction. 4 
  5 
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Materials and Methods 1 
Mice 2 
‘Taiwanese’ (Smn
-/-
;SMN2
tg/0
) model of severe SMA and littermate, heterozygous, 3 
control Smn
+/-
; SMN2
tg/0
: Jackson laboratory stock number 5058) mice were 4 
maintained in the animal care facility at Edinburgh University (Riessland et al., 2010, 5 
Wishart et al., 2014). Mice were retrospectively genotyped using standard PCR 6 
protocols (JAX
®
 Mice Resources). The day of birth is designated as P0. All animal 7 
experiments were performed under appropriate personal and project licenses 8 
granted by the UK Home Office, following internal ethical committee approval from 9 
the University of Edinburgh. 10 
 11 
Tissue Collection 12 
Spleens from SMA and control littermates were harvested from mice sacrificed at 13 
P0, P5 and P8 (pre-, mid- and late-symptomatic respectively (Hunter et al., 2016)) by 14 
overdose of anaesthetic (intra-peritoneal injection of pentobarbital) in accordance 15 
with guidelines from the UK Home Office. Spleens were promptly dissected and fixed 16 
in 4% paraformaldehyde (PFA) in 0.1M phosphate buffered saline for 3 hours. 17 
Spleens were weighed post-fixation, and prepared for cryosectioning in 30% sucrose 18 
solution in 0.1M phosphate buffered saline, emb dded in OCT at -35˚C, sectioned at 19 
8µm and stored at -20˚C before staining. 20 
 21 
Quantitative Fluorescent Western Blotting 22 
Spleens were harvested from mice sacrificed at P8 (late-symptomatic) by overdose 23 
of anaesthetic and stored at -80˚C. Total protein was isolated and homogenised in 24 
40µl of RIPA buffer (Pierce, Cat No. 89900) with 2.5% proteinase inhibitor cocktail 25 
(Thermo Scientific, Cat No. 1861278). Protein concentrations were determined using 26 
a BCA assay kit (Pierce, Cat No. 23225). Protein was separated by SDS-27 
polyacrylamide gel electrophoresis on precast NuPage 4-12% Bis-Tris gradient gels 28 
(Thermo Fisher Scientific, Cat No. NP0323) and transferred to a nitrocellulose 29 
membrane using the iBlot® 2 Gel Transfer Device (Thermo Fisher Scientific, Cat No. 30 
IB2001) and transfer stack (Thermo Fisher Scientific, Cat No. IB23002). Membranes 31 
were blocked using SEA Block (Thermo Fisher Scientific, Cat No. 37527) and 32 
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incubated with anti-SMN antibody (BD Biosciences, Cat No. 610646) overnight. 1 
Membranes were incubated for 1.5 hours in donkey anti-mouse IgG H&L AlexaFluor 2 
790 secondary (ab186699). Blots were imaged using an Odyssey Infrared Imaging 3 
System (LI-COR Biosciences). Total protein was measured by incubating a seperately 4 
electrophoresed gel in Instant Blue (Expedeon, Cat No. ISB1) for 1 hour and scanning 5 
on the Odyssey Infrared Imaging System. SMN protein levels were normalised to 6 
total protein levels using Image Studio Software (LI-COR Biosciences). 7 
 8 
Histological Staining 9 
Standard haematoxylin and eosin (Cardiff et al., 2014)and picro-sirius red staining 10 
(Junqueira et al., 1979) were performed on sections to observe basic architecture of 11 
the spleen. 12 
 13 
Immunohistochemistry 14 
Sections of spleens were air dried for 30 minutes and blocked in standard blocking 15 
solution (0.4% Bovine Serum Albumin (BSA), 1% Triton X-100 in PBS in 0.1M 16 
phosphate buffered saline) for 45 minutes at room temperature. Sections were then 17 
incubated in primary antibodies overnight at 4˚C: PECAM-1 (R&D Systems Cat. No. 18 
AF3628; 1:750); biotinylated CD45R (Life Technologies Cat No. RM2615; 1:200); 19 
CD41 (AbD Serotec Cat. No. MCA2245GA; 1:1000); Ki67 (Abcam Cat. No. ab16667); 20 
and TUNEL in situ cell death kit (Roche Diagnostics Cat No. 11684795910). Sections 21 
were washed and incubated with secondary antibodies for 1 hour at 4˚C: Donkey 22 
anti-goat Cy3 (Abcam Cat No. AB6949; 1:250), streptavidin conjugated AlexaFluor 23 
488 (Life Technologies Cat No. S-11223; 1:200), Goat anti-rat AlexaFluor 488 (Abcam 24 
Cat. No. ab150157; 1:200), and Goat anti-rabbit AlexaFluor 568 (Abcam Cat. No. 25 
ab175471). Sections were washed and cover slipped in MOWIOL mounting media 26 
containing DAPI. 27 
 28 
White Blood Cell Differential 29 
P8 control and SMA mice were culled using termination by exsanguination. Under 30 
isofluorane-induced terminal anaesthesia the thoracic cavity was opened and 31 
cardiac puncture to the left ventricle quickly performed. Blood was withdrawn using 32 
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a 30gauge 0.3ml insulin syringe with one drop of blood used to make a blood smear 1 
(left to air dry) and the remaining placed in a 1.5ml tube with 0.5M EDTA as an 2 
anticoagulant (1:20 ratio with blood) and inverted to mix well. Samples on ice were 3 
immediately taken for WBC differential analysis at the Veterinary Pathology Unit, 4 
University of Edinburgh. Results are expressed as a percentage per 1,000mL of 5 
blood. 6 
 7 
Imaging and Quantification 8 
Microscopy was performed in the Microscope and Histology Core Facility at the 9 
University of Aberdeen. Fluorescent stained slides were viewed using a Zeiss Imager 10 
M2 microscope with Zeiss Apotome, and images were captured with a Zeiss Mrm 11 
digital camera. For nuclear imaging and analysis of cell density a Zeiss confocal 12 
LSM710 microscope and ImageJ were used. Cell Density was calculated using DAPI 13 
labeling and counted using a systematic, random methodology, based on(Mayhew 14 
and Sharma, 1984). Spleens were embedded without specific alignment, and a grid 15 
overlay was placed over a randomly oriented section. From the top left every 3
rd
 grid 16 
square was counted (whole nucleus within or touching top and right hand edges 17 
counted, but not counted if touching bottom or left hand edges of sampling box). 18 
Proliferating cells were counted using a modification of this method, separating data 19 
into central and peripheral zones of the spleen. Full grid squares within 100µm of 20 
the edge of the spleen were counted as peripheral; and full grid squares more than 21 
100µm from the edge were counted as central. Data is expressed as cells Per Unit 22 
Area (PUA). 23 
 24 
Quantification of relative vessel area was achieved using ImageJ. PECAM-1 stained 25 
images were converted to binary, and the number of white (PECAM-1 positive) pixels 26 
were counted as a percentage of the total area. This was performed in 10 fields per 27 
spleen from 6 spleens (n=3 for each genotype). 28 
 29 
SMA patient autopsies 30 
Data on type I SMA human subjects was obtained from review of research 31 
documentation obtained at the time of autopsy and from analysis of patient tissues 32 
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obtained post-mortem. Prior to initiation of any studies, written informed consent 1 
was obtained from the parents to perform a research autopsy under IRB 8751, 2 
reviewed and approved by the University of Utah Institutional Review Board. 3 
Autopsies were performed in collaboration with pathologists at each of the US 4 
institutions involved in this multicenter study (Primary Children’s Medical Center and 5 
the Medical Examiner’s Office, Salt Lake City, UT; Cook Children’s Medical Center, Ft 6 
Worth, TX; Children’s Hospital of Atlanta Scottish Rite, Atlanta, GA).  7 
 8 
Statistical Analysis 9 
Analysis and statistical tests were carried out using GraphPad Prism software 10 
(GraphPad Software Inc.). All data are presented as mean ± SEM. Unless stated 11 
otherwise, statistical tests were unpaired, two-tailed t-tests, with significance 12 
considered to be p<0.05. 13 
  14 
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Results 1 
 2 
The spleen fails to develop correctly in severe SMA mice 3 
On initial inspection at birth (P0), there were no gross differences in the form or size 4 
of the spleen between SMA and control littermate mice. However, by P5 dramatic 5 
differences were present, which further increased by P8, when the spleen was very 6 
small and pale in appearance [Fig. 1A]. We confirmed disease-indicative, low SMN 7 
protein levels in SMA spleen by western blot at P8 (Fig 1B). Quantification confirmed 8 
these qualitative observations, as after birth the spleen failed to increase in size in 9 
SMA mice, and was significantly smaller at both P5 (mid-symptomatic in terms of 10 
neuromuscular pathology: ~87%: p<0.01), and P8 (late symptomatic: ~94%: 11 
p<0.0001) compared to control, age-matched littermates [Fig. 1C]. Importantly, the 12 
SMA spleen was disproportionately small, weighing only 0.1% (n=3; 0.1% ± 0.002%) 13 
compared to 0.6% (n=3; 0.6%±0.034) of total body weight in control mice at P8 [Fig 14 
1D].  15 
 16 
To further investigate the basis of this postnatal developmental phenotype, cell 17 
density was measured by counting DAPI-stained cell nuclei. Cell density increased in 18 
control spleens from birth to P5 and then was maintained at a relatively consistent 19 
level until P8 (P0 9.96±1.03 PUA, n=3; P5 18.03±0.82 PUA, n=3). SMA spleen showed 20 
a similar pattern until P5, with no significant differences from control (P0 11.0±1.77 21 
PUA, n=3; P5 15.8±2.57 PUA, n=3), but by P8 cell density in the spleen was 22 
significantly reduced (<50%) (6.83±0.91 cells per unit area: PUA, n=3; P8 p<0.005) 23 
compared with control littermates (15.58±1.22 PUA; n=3; P8) [Fig. 1E]. 24 
In summary, the spleen appeared normal at birth in SMA mice, but then failed to 25 
grow and develop correctly, lacking the internal organisation observed in the spleen 26 
from healthy control animals.  27 
 28 
Altered proliferation and cell death profiles underlie decreased spleen size  29 
Given the significant difference in size and cell density between control and SMA 30 
spleens, we sought to further investigate this by analysing the distribution of 31 
proliferating and apoptotic cells. In the pre-symptomatic spleen (P0), numbers of 32 
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proliferating cells in both control and SMA spleens were relatively high, and evenly 1 
distributed throughout the spleen [Fig. 2A]. By the mid-symptomatic stage (P5) there 2 
were significantly greater numbers of proliferating cells in the periphery of the SMA 3 
spleen (18.67±0.5 PUA; n=3; P5 p<0.001) compared with the periphery of control 4 
spleen (15.0±0.71 PUA, n=3; P5) [Fig. 2B]. Conversely, at this point proliferation in 5 
the centre was dramatically reduced in control and SMA spleens (Control: 3.0±0.69, 6 
n=3; SMA; 3.67±1.04, n=3; P5). Interestingly, at P8 there was a significant decrease in 7 
proliferating cell numbers in both the centre and periphery of the SMA spleen [Fig. 8 
2C] (centre: p<0.0001; 0.88±0.35, n=3; P8; periphery: p<0.005; 5.88±0.53, n=3; P8), 9 
compared with the control spleen (centre: 8.44±0.92, n=3; P8; periphery; 9.0±0.74, 10 
n=3; P8).  The general pattern suggests that proliferation falls dramatically in the late 11 
symptomatic SMA spleen. 12 
On initial observation of the pre-symptomatic spleen (P0), cell death was more 13 
prevalent at the periphery of the spleen in both control and SMA mice, however 14 
there was no significant difference between the two [Fig. 2D]. By the mid-15 
symptomatic (P5) stage there were ~7x more apoptotic cells at the periphery of the 16 
SMA spleen [Fig. 2E](****p<0.0001; 2.62±0.31 PUA, n=3; P5) compared with the 17 
control spleen (0.36±0.27 PUA, n=3). The apoptotic cells appeared to be confined to 18 
the extreme periphery and were likely capsule cells. Finally, by late-symptomatic 19 
stage (P8) cell death occurred more uniformly throughout the splenic tissue in both 20 
control and SMA spleens [Fig. 2F], with no significant differences. In summary, cell 21 
death was generally variable but relatively low throughout all regions, and between 22 
SMA and control spleens. The exception was at P5 where there was a dramatic 23 
increase in cell death in peripheral cells in SMA spleen. 24 
 25 
Morphologically distinct white pulps fails to develop and ultimately the spleen 26 
begins to degenerate in SMA mice 27 
Next, we used haematoxylin and eosin stained histological preparations from SMA 28 
and control mouse spleen to assess cellular morphology. At P0 the white pulp had 29 
not aggregated in control spleen and there were no clear differences between 30 
control and SMA spleen (data not shown). In control spleen at P8, as expected, 31 
clearly differentiated islands of white pulp surrounding central arterioles within a 32 
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mass of red pulp were present, and the surrounding capsule and centrally projecting 1 
fingers of trabeculae were well developed [Fig 3A]. However, in SMA spleen the 2 
appearance was strikingly different. Here, the tissue appeared homogeneous, with 3 
no apparent segregation of white pulp, and an overall appearance most closely 4 
resembling homogeneous red pulp [Fig.3D]. This suggests either a failure to develop, 5 
or incomplete migration and segregation of cells into red and white pulp areas. In 6 
addition, no clear capsule was observed surrounding the SMA spleen [Fig. 3E], which 7 
may account for its very fragile nature at dissection. To further examine this, we 8 
used Picro Sirius Red to stain the collagen fibres, which are a major constituent of 9 
the capsule and trabeculae. Control spleen had a well developed and organised 10 
fibrous framework, as predicted [Fig. 3C], while SMA spleen showed almost no 11 
collagen where the capsule should be present and a highly disorganised internal 12 
arrangement [Fig. 3F]. This indicates the presence of fibrosis and degenerative 13 
processes within the spleen of SMA mice. 14 
 15 
Vascular density is not affected in the SMA spleen 16 
To further understand the aetiology of the aberrant lymphoid tissue development in 17 
SMA spleen, we turned our attention to its vascular supply. As a blood filter, the 18 
vascular development within the spleen is critical for proper function (Cesta, 2006). 19 
We carried out PECAM-1 (an endothelial cell marker) immunohistochemistry on 20 
spleens from P0, P5 and P8 mice. Initial qualitative observations showed no apparent 21 
difference in either the form or density of the vascular component in SMA mice [Fig 22 
4].  Quantitative assessment of the vasculature at each time point confirmed that 23 
there were no differences between SMA and control spleens (SMA P0, 4.94% ± 0.66; 24 
control P0, 6.39%±0.57; SMA P5, 5.21%±0.29; control P5, 4.63%±0.77; SMA P8, 25 
5.92%±0.42; control P8, 6.38%±0.29) [Fig 4]. Thus, the defects observed in the spleen 26 
of SMA mice are unlikely to represent a secondary consequence of vascular defects 27 
previously reported elsewhere in the body (Somers et al., 2012, Somers et al., 2016). 28 
 29 
Developing B-cell follicles are absent in SMA spleen  30 
To further investigate the apparent failure of white pulp aggregation in SMA spleen, 31 
we next examined B-cell lymphocytes, which are necessary for normal immune 32 
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functions of the spleen. CD45R (a pan B-cell marker) in conjunction with PECAM-1 1 
(as above) immunohistochemistry showed regular accumulations of brightly stained 2 
B-cells in control animals, indicative of developing white pulp from P5 onwards [Fig. 3 
5]. Significantly, these were not present in SMA spleen, where only diffuse, 4 
homogeneously distributed and poorly stained B-cells were present. We next carried 5 
out a white blood cell differential blood analysis. This revealed a significantly lower 6 
percentage (**p<0.01) of circulating lymphocytes in the SMA mouse (31.7%±2.77, 7 
n=4) compared with control mice (55.25%±3.96, n=4) [Fig. 5]. Taken together these 8 
findings reveal a striking absence of resident lymphocytes (B-cell follicles) in the 9 
spleen and a similar reduction in circulating lymphocytes in SMA mice. 10 
 11 
Megakaryocyte populations are increased in SMA spleen  12 
Further examination of haematoxylin and eosin stained histological preparations 13 
from SMA and control mouse spleen revealed the presence of many large cells with 14 
lobulated nuclei [Fig. 3G], which we suspected to be megakaryocytes, in SMA 15 
samples. We sought to confirm this by performing immunohistochemical staining 16 
with antibodies against CD41 (a megakaryocyte cell and platelet marker) in control 17 
and late-symptomatic mice [Fig 6. A, B]. We identified megakaryocytes by co-staining 18 
with a DAPI nuclear stain [Fig 6. A, B. inset], as platelets do not contain nuclei. 19 
Quantitative analysis revealed significantly greater numbers (****p<0.0001) of 20 
megakaryocytes in late symptomatic P8 SMA spleen (5.9±0.56, n=3: mean + SEM; 21 
p8) compared to control spleens (1.13±0.18 PUA, n=3; p8) [Fig 6C].  22 
 23 
Preliminary observations of spleen abnormalities in SMA type I patients  24 
We were keen to establish whether any of the defects found in mouse models were 25 
similarly present in human SMA patients. Autopsy samples collected from severe 26 
SMA patients (n=9, SMA type I) aged 6-60 months, revealed that 56% (5 of 9) of 27 
patients demonstrated abnormal splenic pathology, either grossly or upon further 28 
examination of tissues via light microscopy (Table 1). Observed changes included 29 
gross defects such as increased white pulp, small accessory spleens, and congestion 30 
and presence of erythroid precursors in the red pulp.  These findings confirm that 31 
abnormalities in the spleen occur in at least a subset of patients with SMA type I.   32 
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Discussion 1 
Given the historical context of SMA as a clinically-defined motor neuron disease, 2 
most previous research has understandably focussed on key pathological events 3 
surrounding motor neuron loss and muscle atrophy. However, as the protein 4 
product of the SMN gene is expressed ubiquitously in all cells and tissues of the 5 
body, we should perhaps not be surprised that depletion of SMN in SMA results in 6 
pathologies affecting other organ and tissue systems (Hamilton and Gillingwater, 7 
2012, Shababi et al., 2014). Here, we extend these findings to reveal significant 8 
defects in the gross anatomy and cellular composition of the spleen in an established 9 
mouse model of severe SMA. The spleen was disproportionately small and had a 10 
disturbed architecture, most notable changes were failed B-cell aggregation in white 11 
pulp and an abnormal amount of megakaryocytes present in red pulp. In contrast, 12 
the basic vasculature of the spleen appeared to be unaffected. The defects described 13 
here reflect failed post-natal development of the spleen, resulting in a grossly 14 
deficient and defective organ at postnatal day 10, when these mice display severe 15 
neuromuscular pathology. Importantly, a range of pathologies were also seen at 16 
autopsy in severe SMA patients.  17 
 18 
We have previously reported significant depletion of capillary beds in skeletal muscle 19 
and spinal cord of SMA mice and human SMA patients (Somers et al., 2011, Somers 20 
et al., 2016), resulting in functionally-significant tissue hypoxia (Somers et al., 2016). 21 
We expected to find a similar pathology in the spleen of SMA mice, but were 22 
surprised to find that although the spleen was small and pale in appearance, the 23 
density of the intrinsic vasculature remained unchanged. However, it should be 24 
noted that the vascular development of the spleen is significantly different to that in 25 
muscle and spinal cord. In most organs, vessel ingrowth determines organ growth, 26 
while in muscle and central nervous system, the vasculature grows into expanding 27 
organ systems (Ramasamy et al., 2015, Crivellato et al., 2007). As the SMA spleen is 28 
approximately 20 times smaller, in absolute terms, than the control spleen at late 29 
stages, this could reflect decreased angiogenesis, which then fails to drive organ 30 
expansion. Equally, low numbers of lymphocytes are present in the spleen at birth, 31 
while high levels of proliferating B and T-cells are present in order to form a 32 
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functioning white pulp capable of providing immune responses (Loder et al., 1999, 1 
Le Campion et al., 2002). Therefore, it is unsurprising that the late-symptomatic SMA 2 
spleen with no white pulp has significantly fewer proliferating cells, especially 3 
centrally, where white pulp should be developing. The increased levels of cell 4 
proliferation in the periphery of the SMA spleen at P5 suggest an attempt to 5 
maintain normal splenic growth, however this is countered by a simultaneous 6 
increase in cell death at the periphery. Interestingly, cell death appears to occur 7 
largely in the splenic capsule of the mid-symptomatic SMA spleen, an area we have 8 
shown to be fibrotic and degenerative. The subsequent decrease in cell proliferation 9 
both centrally and peripherally at P8 in the SMA spleen correlates with our reports 10 
of small spleen size and decreased cell density.  11 
The decrease in circulating lymphocytes coupled with the failure of B-cells to 12 
accumulate and form a functional white pulp in SMA mice, suggests a developmental 13 
defect in the immune system. B-cells are generated in bone marrow and must travel 14 
via the circulatory system to the spleen and through the T-cell zone, where they 15 
communicate with activated T-cells and subsequently mature (Forster et al., 1999, 16 
Mebius and Kraal, 2005). Vascular endothelial cells in the spleen are critical for this 17 
lymphocyte homing behaviour from high endothelial venules (Czompoly et al., 2011, 18 
Lee et al., 2014), and a subtle defect in the endothelial cells could lie at the root of 19 
this. However, the decrease in numbers of circulating lymphocytes in the blood 20 
suggests that B-cells may simply not be present in sufficient numbers to aggregate in 21 
the spleen. The spleen should normally contain approximately 25% of the total 22 
number of lymphocytes (Nolte et al., 2002) and the absence of B-cell lymphocytes in 23 
the SMA spleen may be an indicator of a more widespread defect in the immune 24 
system.  25 
 26 
In the red pulp, we observed in an increase in the number of megakaryocytes in SMA 27 
spleen. This evidence of extra-medullary haematopoiesis is suggestive of a secondary 28 
response to a systemic change, most likely hypoxia (Kim, 2010), and we have 29 
previously reported significant hypoxia in these mice at P5 (Somers et al., 2016). 30 
Extra-medullary haematopoiesis, as suggested by the increase in red pulp 31 
megakaryocytes, has been linked to a loss of splenic architecture (Franke et al., 32 
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2013) and may be responsible for the generally disorganised splenic microstructure 1 
in SMA.  2 
We were interested to determine if any changes in gross morphology were present 3 
in the spleen of severe SMA patients, which the mice used in this study most closely 4 
model (Hsieh-Li et al., 2000). When data from routine autopsies were reviewed, we 5 
found that the majority showed some gross or micro-anatomical pathology. The fact 6 
that these abnormalities include both what could be termed developmental and 7 
degenerative pathologies, suggests that the human spleen is a focus of previously 8 
un-described pathology in severe patients and warrants further investigation.  9 
Given that the majority of the defects we have observed in the mouse model would 10 
not be observable at routine autopsy, it is perhaps not surprising that several patient 11 
spleens appear ‘normal’ in macroscopic appearance. However, the variability of both 12 
patient age and observed splenic abnormalities, including absence in some cases, 13 
suggests that further studies are required to examine potential parallels with 14 
observations from the SMA mouse model. 15 
In summary, we show that SMN depletion leads to specific yet varied defects in the 16 
gross and microanatomy of the spleen in a mouse model of severe SMA. Further, a 17 
range of splenic defects were present in severe SMA patients. This is likely to lead to 18 
a significantly compromised immune system in SMA that may have important 19 
implications for the broader spectrum of pathology that occurs in the disease. 20 
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Figure Legends 1 
 2 
Figure 1. SMA spleen is disproportionately small and disorganised 3 
A. Spleen from control (left) and late symptomatic (P8) SMA (right) mice. SMA spleen 4 
appears dramatically smaller and pale in comparison to control spleen. Scale bar = 5 
5mm. B. Quantitative western blot of SMN protein (green) displays a significant 6 
reduction of SMN (~40kDa) in late-symptomatic (P8) SMA spleens (p<0.0001; ~39%) 7 
compared with controls. C. Spleen weights at pre- (P0), mid- (P5), and late-8 
symptomatic (P8) time points. SMA spleens are significantly smaller than control 9 
spleens at both P5 (**p<0.005) and P8 (****p<0.0001). D. As a percentage of total 10 
body weight, spleens are significantly smaller at both p5 (** p<0.05) and P8 11 
(****p<0.0001). E. Quantification shows a significantly reduced density of cells in the 12 
SMA spleen (**p<0.01). 13 
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Figure 2. Cell proliferation and cell death are altered in the SMA spleen 1 
Cell proliferation marker Ki67 (red) and cell death marker TUNEL (green) staining of 2 
pre-, mid- and late-symptomatic mice. A. At the pre-symptomatic stage (P0) cell 3 
proliferation is occurring uniformly throughout splenic tissue in both control and 4 
SMA mice. B. At the mid-symptomatic stage (P5) there is a significant increase in cell 5 
proliferation in the periphery of the SMA spleen (***p<0.005). C. At the late-6 
symptomatic stage (P8) cell proliferation is significantly reduced both centrally 7 
(****p<0.0001) and peripherally (**p<0.01) in SMA mice. Scale bar = 100µm. D. At 8 
birth (P0), apoptosis is largely restricted to the periphery of the spleen in both 9 
control and SMA mice. This continues into the mid-symptomatic stage (P5, E) 10 
however there is a significant increase in cell death in the periphery of the SMA 11 
spleen (****p<0.0001), particularly around the splenic capsule. By the late-12 
symptomatic stage (P8, F) there is no difference in occurrence of cell death between 13 
the control and SMA spleens. Scale bar = 50µm. 14 
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Figure 3. A morphologically distinct white pulps fails to develop and the spleen 1 
begins to degenerate in SMA mice 2 
H&E staining of late-symptomatic (p8) spleens. A. In the control spleen, white pulp 3 
(dotted line) is clearly separated from red pulp. D. In the SMA spleen red and white 4 
pulp are indiscernible from one another, and there is an accumulation of large cells 5 
with lobulated nuclei (arrowhead, G). Scale bar: 50µm. B. Control spleen displays an 6 
intact splenic capsule, whereas the SMA spleen lacks a smooth and organised 7 
capsule-like structure, instead presenting apparent dissociation of capsular cells (E). 8 
Scale bar = 20µm. C, F. Picro-Sirius Red staining of the collagen component of the 9 
splenic capsule and trabeculae (arrowhead) in the control and late-symptomatic (p8) 10 
spleen. The splenic capsule and trabeculae are intact in the control spleen (C), 11 
however the SMA spleen lacks trabeculae, and shows dissociation of the capsule (F). 12 
Scale bar = 50µm. 13 
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Figure 4. The intrinsic vasculature of the spleen is unaltered in SMA 1 
Endothelial cell marker PECAM-1 stained vasculature throughout spleens of pre-, 2 
mid- and late-symptomatic mice. Distribution of vasculature appears uniform 3 
throughout the tissue of both control and SMA tissue. Analysis of fractional vessel 4 
area indicates no change during development and no significant differences between 5 
control and SMA at any time point. Scale bar = 50µm.  6 
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Figure 5. B cells fail to accumulate in SMA spleen and circulating lymphocyte count is 1 
reduced 2 
B cell marker CD45R (green) demonstrates clusters of B cells have begun forming follicles 3 
in mid (P5)- and late (P8)-symptomatic control spleens, but not in mid- to late-4 
symptomatic SMA spleens where B cells are absent. Circulating lymphocyte counts were 5 
significantly decreased in SMA mice (SMA n=4, control n=4; ** p<0.005). Scale bar = 6 
100µm. 7 
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Figure 6. Megakaryocytes persist in SMA spleen but platelet numbers are unaltered 1 
CD41 stained cells in p8 spleens from control (A) and SMA (B) mice.  There are 2 
significantly greater numbers of positively stained CD41
+
 nucleated megakaryocytes 3 
(inset) PUA present in the late-symptomatic (P8) SMA spleen compared with the 4 
control spleen (C). (****p<0.0001). Scale bar = 25µm.  5 
 6 
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Figure 1. SMA spleen is disproportionately small and disorganised  
A. Spleen from control (left) and late symptomatic (P8) SMA (right) mice. SMA spleen appears dramatically 
smaller and pale in comparison to control spleen. Scale bar = 5mm. B. Quantitative western blot of SMN 
protein (green) displays a significant reduction of SMN (~40kDa) in late-symptomatic (P8) SMA spleens 
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symptomatic (P8) time points. SMA spleens are significantly smaller than control spleens at both P5 
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Figure 2. Cell proliferation and cell death are altered in the SMA spleen  
Cell proliferation marker Ki67 (red) and cell death marker TUNEL (green) staining of pre-, mid- and late-
symptomatic mice. A. At the pre-symptomatic stage (P0) cell proliferation is occurring uniformly throughout 
splenic tissue in both control and SMA mice. B. At the mid-symptomatic stage (P5) there is a significant 
increase in cell proliferation in the periphery of the SMA spleen (***p<0.005). C. At the late-symptomatic 
stage (P8) cell proliferation is significantly reduced both centrally (****p<0.0001) and peripherally 
(**p<0.01) in SMA mice. Scale bar = 100µm. D. At birth (P0), apoptosis is largely restricted to the 
periphery of the spleen in both control and SMA mice. This continues into the mid-symptomatic stage (P5, 
E) however there is a significant increase in cell death in the periphery of the SMA spleen (****p<0.0001), 
particularly around the splenic capsule. By the late-symptomatic stage (P8, F) there is no difference in 
occurrence of cell death between the control and SMA spleens. Scale bar = 50µm.  
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Figure 3. A morphologically distinct white pulps fails to develop and the spleen begins to degenerate in SMA 
mice  
H&E staining of late-symptomatic (p8) spleens. A. In the control spleen, white pulp (dotted line) is clearly 
separated from red pulp. D. In the SMA spleen red and white pulp are indiscernible from one another, and 
there is an accumulation of large cells with lobulated nuclei (arrowhead, G). Scale bar: 50µm. B. Control 
spleen displays an intact splenic capsule, whereas the SMA spleen lacks a smooth and organised capsule-like 
structure, instead presenting apparent dissociation of capsular cells (E). Scale bar = 20µm. C, F. Picro-Sirius 
Red staining of the collagen component of the splenic capsule and trabeculae (arrowhead) in the control and 
late-symptomatic (p8) spleen. The splenic capsule and trabeculae are intact in the control spleen (C), 
however the SMA spleen lacks trabeculae, and shows dissociation of the capsule (F). Scale bar = 50µm.  
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Figure 4. The intrinsic vasculature of the spleen is unaltered in SMA  
Endothelial cell marker PECAM-1 stained vasculature throughout spleens of pre-, mid- and late-symptomatic 
mice. Distribution of vasculature appears uniform throughout the tissue of both control and SMA tissue. 
Analysis of fractional vessel area indicates no change during development and no significant differences 
between control and SMA at any time point. Scale bar = 50µm.  
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Figure 5. B cells fail to accumulate in SMA spleen and circulating lymphocyte count is reduced  
B cell marker CD45R (green) demonstrates clusters of B cells have begun forming follicles in mid (P5)- and 
late (P8)-symptomatic control spleens, but not in mid- to late-symptomatic SMA spleens where B cells are 
absent. Circulating lymphocyte counts were significantly decreased in SMA mice (SMA n=4, control n=4; ** 
p<0.005). Scale bar = 100µm.  
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Figure 6. Megakaryocytes persist in SMA spleen but platelet numbers are unaltered  
CD41 stained cells in p8 spleens from control (A) and SMA (B) mice.  There are significantly greater 
numbers of positively stained CD41+ nucleated megakaryocytes (inset) PUA present in the late-
symptomatic (P8) SMA spleen compared with the control spleen (C). (****p<0.0001). Scale bar = 25µm.  
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Table 1.  
 
SMA Type I routine spleen autopsy results 
Age (months) Abnormalities 
6 Accessory spleen 
14 Congested red pulp 
16 Accessory spleen 
21 None 
28 Increased white pulp and erythroid precursors 
33 None 
35 None 
45 Congested red pulp 
60 None 
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